X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, is being evaluated in the Phase 2/3 clinical trials for the treatment of patients with metastatic or locally advanced biliary tract tumors.
Lead Product(s): CTX-009,Paclitaxel
Therapeutic Area: Oncology Product Name: CTX-009
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1. It is being evaluated for the treatment of solid tumors like non small cell lung cancer, triple negative breast cancer & hodgkin lymphoma.
Lead Product(s): CTX-8371
Therapeutic Area: Oncology Product Name: CTX-8371
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch and VEGF-A signaling pathways, which are critical to angiogenesis and tumor vascularization.
Lead Product(s): CTX-009,Paclitaxel
Therapeutic Area: Oncology Product Name: CTX-009
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch and VEGF-A signaling pathways, which are critical to angiogenesis and tumor vascularization, providing robust anti-tumor activity across several solid tumors.
Lead Product(s): CTX-009
Therapeutic Area: Oncology Product Name: CTX-009
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization.
Lead Product(s): CTX-009,Paclitaxel
Therapeutic Area: Oncology Product Name: CTX-009
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
CTX-471 is a fully human IgG4 agonistic antibody that binds to a unique epitope of the CD137 receptor that has a co-stimulatory effect on T-Cells and NK Cells, two important components of the innate immune system.
Lead Product(s): CTX-471,Pembrolizumab
Therapeutic Area: Oncology Product Name: CTX-471
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
CTX-009 (asciminib), a bispecific antibody demonstrated a 42% overall response rate (ORR) based on 10 patients with Partial Responses (PRs), including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation.
Lead Product(s): Asciminib,Paclitaxel
Therapeutic Area: Oncology Product Name: CTX-009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
CTX-009 (asciminib) is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), also has demonstrated clinical benefit in heavily pre-treated patients who have progressed after prior targeted therapies.
Lead Product(s): Asciminib,Paclitaxel
Therapeutic Area: Oncology Product Name: CTX-009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
CTX-8371 is a bispecific antibody that simultaneously targets the programmed death receptor (PD-1) and the programmed death receptor ligand (PD-L1) that are expressed on immune cells and cancer cells.
Lead Product(s): CTX-8371
Therapeutic Area: Oncology Product Name: CTX-8371
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 that are expressed on immune cells and cancer cells, is currently undergoing IND-enabling preclinical development.
Lead Product(s): CTX-8371
Therapeutic Area: Oncology Product Name: CTX-8371
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
